Science behind Company’s Skin Health & Beauty brands,
including Neutrogena®, Aveeno® and more, demonstrates commitment to
advancing everyday skin care
Kenvue Inc. (“Kenvue”), the world’s largest pure-play
consumer health company by revenue, will share new data
demonstrating how its iconic brands are contributing to the
advancement of everyday skin care at the American Academy of
Dermatology (AAD) Association Annual Meeting, set for March 8-12 at
the San Diego Convention Center in San Diego, California.
In findings from the 22 data sets detailing new Kenvue skin
science research, industry experts will present evidence confirming
the clinical effectiveness of Neutrogena® and Aveeno® formulations
in moisturizing skin, improving skin barrier, protecting against
UVA sun damage, and rapidly reducing facial acne. Kenvue will also
offer hands-on experiences in exhibit-floor Booth 2511, featuring
products that are household names, including those from the
Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and
Rogaine®1 portfolios.
“This is our first time presenting as Kenvue at the annual AAD
meeting, allowing us a great opportunity to meet with leaders
across dermatology and share our latest category-defining research
that supports the value of our iconic brands as a part of everyday
care,” said Adam Ricciardone2, Head of R&D, Global Skin Health
& Beauty and Head of R&D North America. “This evidence
illustrates our ongoing commitment to delivering science-backed,
care-forward experiences that are loved by consumers and
recommended by healthcare professionals and experts.”
In six new clinical studies being presented at AAD, Kenvue
investigators found that oat-containing moisturizers developed by
Aveeno® and Neutrogena® scientists made the skin’s microbiome more
resilient in a variety of populations. These include young children
predisposed to eczema, women with dry skin, adults with mild to
moderate eczema, and adults receiving immunobiological treatment
for psoriasis.
Across these studies, findings showed that consumers enjoyed
improved quality of life while using the moisturizing formulations
— and, in many cases, for days afterwards or even longer.
Specifically, product users experienced less itchiness, scaliness
and self-consciousness about their appearance — or, in the case of
the infants, improvements to the skin’s microbiome associated with
a decreased risk of eczema.
Additional data to be presented at AAD demonstrates the benefits
of Kenvue’s formulations for skin hydration, sun protection and
acne control.
Studies presented will include:
Novel Natural Moisturizing Factor and Lipid-Containing Face
Cream Induces Aquaporin-3 and Filaggrin Expression Associated with
Barrier Improvements and Sustained Clinical Hydration in Extra-Dry
Skin; Bernhardt KT, et al.
Demonstrating the Clinical Effectiveness of Mineral
Sunscreens in Protecting the Skin Against Ultraviolet A (UVA)
Radiation-Induced Pigmentation; Shyr TC, et al.
The Science Behind a Viral Trend: Demonstrating Tolerance and
Efficacy of Hydrocolloid Patch for Facial Acne; Kosmoski G, et
al.
On Friday and Saturday, Kenvue experts and key opinion leaders
will also host R&D Theater presentations in the booth. See here
for a full list of topics and times.
Kenvue’s exhibit-floor Booth 2511 will offer ongoing education
and experiences. On Friday and Saturday, Kenvue experts and
dermatological key opinion leaders will also host 10 R&D
Theater presentations in the theater section of the booth, covering
a variety of skin concerns, new formulas, and data. Other product
and ingredient experiences to engage dermatologists include “tiny
mic”-style interviews, oat-science trivia presented by Aveeno®, and
Neutrogena® conversations with SkinU scientists and a mega
influencer.
About Kenvue
Kenvue is the world’s largest pure-play consumer health company
by revenue. Built on more than a century of heritage and propelled
forward by science, our iconic brands — including Aveeno®,
BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®,
Neutrogena®, Tylenol® and Zyrtec® — are recommended by health care
professionals and can be trusted by consumers who use our products
to improve their daily lives. Our team members share a
digital-first mindset, with an approach to innovation grounded in
deep human insights and work every day to earn a place for our
products in consumers’ hearts and homes. At Kenvue, we believe
everyday care can not only make people well; it can make them
whole. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995
regarding data being presented at the American Academy of
Dermatologists Annual Meeting. Forward-looking statements may be
identified by the use of words such as “plans,” “expects,” “will,”
“anticipates,” “estimates” and other words of similar meaning. The
reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Kenvue
Inc. (“Kenvue”) and its affiliates.
A list and descriptions of risks, uncertainties and other
factors can be found in Kenvue’s filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the fiscal year ended December 31, 2023 and subsequent Quarterly
Reports on Form 10-Q and other filings, available at www.kenvue.com
or on request from Kenvue. Kenvue and its affiliates undertake no
obligation to update any forward-looking statements, whether as a
result of new information, future events or developments or
otherwise.
____________________________ 1 Neutrogena®, Aveeno®, NeoStrata®,
Lubriderm®, Band-Aid Brand® and Rogaine® are brands of Johnson
& Johnson Consumer Inc., a subsidiary of Kenvue. 2 Adam
Ricciardone is an employee of Johnson & Johnson Consumer Inc.,
a subsidiary of Kenvue.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306523598/en/
R&D Media Relations Meghan Harding
mhardin1@kenvue.com Media Relations media@kenvue.com
Kenvue (NYSE:KVUE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Kenvue (NYSE:KVUE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024